Limits...
Protective effect of rosuvastatin treatment by regulating oxidized low-density lipoprotein expression in a rat model of liver fibrosis

View Article: PubMed Central - PubMed

ABSTRACT

The present study aimed to evaluate the protective effect of rosuvastatin treatment on the mechanism of oxidized low-density lipoprotein (Ox-LDL) in rats with liver fibrosis. In total, 72 male Sprague-Dawley rats were divided into 3 groups: 24 in the control group (A), 24 in the obstructive jaundice models group (B) and 24 in the rosuvastatin group (C). Each group was further divided into four subgroups for assessment at different time-points. The obstructive jaundice models were established and rosuvastatin was administered by gavage. Liver fibrosis indicators, Ox-LDL, malonaldehyde (MDA) and superoxide dismutase (SOD), were measured and liver pathological changes were observed at weeks 1, 2, 3 and 4 after model induction. In groups B and C, the rat models were successfully established, and there were significant changes in the expression of Ox-LDL and the three liver fibrosis indicators when compared to group A (P<0.01). However, the expression of Ox-LDL and the three liver fibrosis indicators in group C were decreased compared with group B (P<0.05), while SOD increased (P<0.05) and MDA decreased (P<0.05). The three liver fibrosis indicators were different in comparison to group B (P<0.05). Thus, there appeared to be an association between the expression of Ox-LDL and liver fibrosis. Treatment with rosuvastatin could regulate the expression of Ox-LDL and improve liver fibrosis in rat models with obstructive jaundice.

No MeSH data available.


Related in: MedlinePlus

Expression of Ox-LDL in the different groups (magnification, ×400). Ox-LDL staining was weaker in (A) group A compared to groups (B) C and (C) B. Group B had stronger expression of Ox-LDL compared to group C. The staining score of A was graded as 1, B was 3, and C was 5. Ox-LDL, oxidized low-density lipoprotein.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998105&req=5

f3-br-0-0-722: Expression of Ox-LDL in the different groups (magnification, ×400). Ox-LDL staining was weaker in (A) group A compared to groups (B) C and (C) B. Group B had stronger expression of Ox-LDL compared to group C. The staining score of A was graded as 1, B was 3, and C was 5. Ox-LDL, oxidized low-density lipoprotein.

Mentions: The expression level of Ox-LDL was observed by immunofluorescence. As shown in Fig. 3, Ox-LDL was located in the hepatocyte membrane. Table III showed that the expression levels of Ox-LDL were considerably elevated in groups B (P<0.01) and C (P<0.01) compared with group A at weeks 3 and 4. However, the expression levels of Ox-LDL were decreased in group C compared with group B (P<0.05).


Protective effect of rosuvastatin treatment by regulating oxidized low-density lipoprotein expression in a rat model of liver fibrosis
Expression of Ox-LDL in the different groups (magnification, ×400). Ox-LDL staining was weaker in (A) group A compared to groups (B) C and (C) B. Group B had stronger expression of Ox-LDL compared to group C. The staining score of A was graded as 1, B was 3, and C was 5. Ox-LDL, oxidized low-density lipoprotein.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998105&req=5

f3-br-0-0-722: Expression of Ox-LDL in the different groups (magnification, ×400). Ox-LDL staining was weaker in (A) group A compared to groups (B) C and (C) B. Group B had stronger expression of Ox-LDL compared to group C. The staining score of A was graded as 1, B was 3, and C was 5. Ox-LDL, oxidized low-density lipoprotein.
Mentions: The expression level of Ox-LDL was observed by immunofluorescence. As shown in Fig. 3, Ox-LDL was located in the hepatocyte membrane. Table III showed that the expression levels of Ox-LDL were considerably elevated in groups B (P<0.01) and C (P<0.01) compared with group A at weeks 3 and 4. However, the expression levels of Ox-LDL were decreased in group C compared with group B (P<0.05).

View Article: PubMed Central - PubMed

ABSTRACT

The present study aimed to evaluate the protective effect of rosuvastatin treatment on the mechanism of oxidized low-density lipoprotein (Ox-LDL) in rats with liver fibrosis. In total, 72 male Sprague-Dawley rats were divided into 3 groups: 24 in the control group (A), 24 in the obstructive jaundice models group (B) and 24 in the rosuvastatin group (C). Each group was further divided into four subgroups for assessment at different time-points. The obstructive jaundice models were established and rosuvastatin was administered by gavage. Liver fibrosis indicators, Ox-LDL, malonaldehyde (MDA) and superoxide dismutase (SOD), were measured and liver pathological changes were observed at weeks 1, 2, 3 and 4 after model induction. In groups B and C, the rat models were successfully established, and there were significant changes in the expression of Ox-LDL and the three liver fibrosis indicators when compared to group A (P&lt;0.01). However, the expression of Ox-LDL and the three liver fibrosis indicators in group C were decreased compared with group B (P&lt;0.05), while SOD increased (P&lt;0.05) and MDA decreased (P&lt;0.05). The three liver fibrosis indicators were different in comparison to group B (P&lt;0.05). Thus, there appeared to be an association between the expression of Ox-LDL and liver fibrosis. Treatment with rosuvastatin could regulate the expression of Ox-LDL and improve liver fibrosis in rat models with obstructive jaundice.

No MeSH data available.


Related in: MedlinePlus